Follistatin 344 Dosage Guide: Protocols, Isoforms, and Myostatin Data (2026)

Follistatin is a naturally occurring glycoprotein produced primarily in the liver, skin, and folliculostellate cells of the pituitary gland. Its primary function is binding and neutralizing members of the TGF-beta superfamily, specifically myostatin (GDF-8), activin A, and activin B.

Myostatin is a negative regulator of muscle mass. Animals with myostatin gene knockouts develop dramatically increased musculature. The famous Belgian Blue cattle carry a natural myostatin mutation and pack roughly twice the muscle of normal cattle. In humans, a child with a myostatin loss-of-function mutation was documented with visible muscular hypertrophy at birth (Schuelke et al. 2004, PubMed 15215484).

Follistatin works by trapping myostatin in a high-affinity complex (Kd ~5-10 pM), preventing it from binding to the activin type II receptor (ActRIIB) on muscle cells. With the myostatin signal blocked, satellite cell proliferation increases and protein synthesis tilts toward net accretion.

Why "344" specifically? The number refers to amino acid count. The FST gene produces a 344-amino-acid precursor protein. After secretion, FS-344 undergoes C-terminal cleavage to produce shorter isoforms. FS-315 (the main circulating form) targets muscle. FS-288 (tissue-bound) concentrates in reproductive organs. When you inject recombinant FS-344, your body converts most of it to FS-315 in the bloodstream.

Follistatin 344 dosing differs from standard peptide protocols. There is no loading phase. Cycle length, not daily dose, is the main variable.

Follistatin 344 is not the only approach to myostatin inhibition. Several compounds target the same pathway through different mechanisms. Understanding the landscape helps contextualize follistatin's position.

ACE-031 (developed by Acceleron Pharma) showed promising muscle-building results in Phase I trials but was discontinued after Phase II due to adverse events including nosebleeds and small dilated blood vessels. The problem: ACE-031 blocks activin broadly, affecting pathways beyond muscle (Campbell et al. 2017, PubMed 27779229).

Follistatin's advantage is specificity. It binds myostatin with extremely high affinity while its isoform distribution (FS-315 to muscle, FS-288 to gonads) provides some tissue selectivity. The trade-off is a short circulating half-life requiring daily injection, versus gene therapy approaches that produce sustained expression from a single treatment.

For a broader view of peptides for muscle growth, follistatin sits at the most direct end of the myostatin inhibition spectrum. Growth hormone secretagogues like ipamorelin, GHRP-2, or MK-677 work through entirely different pathways (GH/IGF-1 axis) and can be stacked with follistatin without overlapping mechanisms.

Follistatin 344 is more fragile than standard synthetic peptides. It is a full-length protein that can denature with rough handling, excessive heat, or contamination.

Reconstitution steps:

1. 1.Allow the lyophilized vial to reach room temperature (5-10 minutes).
2. 2.Wipe the stopper of both the follistatin vial and the bacteriostatic water vial with an alcohol swab.
3. 3.Draw 0.5 mL of bacteriostatic water per 1 mg of follistatin powder. For a 1 mg vial, use 0.5 mL. This produces a concentration of 200 mcg per 0.1 mL (10 IU on an insulin syringe).
4. 4.Inject the water slowly down the inside wall of the vial at a 45-degree angle. Do not squirt directly onto the powder.
5. 5.Gently swirl the vial until the powder dissolves completely. Never shake.
6. 6.The solution should be clear. Discard if cloudy or if particulates are visible.

Use our reconstitution calculator to determine exact volumes for your vial size and desired dose per injection.

Storage requirements:

Reconstituted follistatin degrades faster than most peptides. The protein's large size and complex tertiary structure make it susceptible to thermal denaturation. Use within 7 days of reconstitution for best potency. If you cannot use the full vial in 7 days, aliquot into multiple sterile vials and freeze the extras at -20°C.

For detailed reconstitution technique, see our guide on how to reconstitute peptides. Injection technique is covered in the peptide injections guide.

Follistatin 344 has a limited human safety profile. The gene therapy data (Minicircle, 500+ patients) reported zero serious adverse events at 3 months. The most common effect was a slight LDL cholesterol increase of 8 mg/dL in approximately one-third of patients.

Reported side effects from practitioner protocols:

Critical safety concerns:

Fertility impact: Follistatin inhibits pituitary FSH (follicle-stimulating hormone) release. In women, FSH drives ovarian follicle development. In men, FSH supports spermatogenesis. Artificially elevated follistatin may suppress FSH and impair fertility during the cycle. This effect should reverse off-cycle, but couples actively trying to conceive should avoid follistatin. The Kota 2009 primate study found no permanent reproductive effects, but short-term suppression was not measured (PubMed 19208403).

Eye concerns (CSCR): A published case series documented central serous chorioretinopathy (CSCR) in 11 bodybuilders using high-dose follistatin 344. CSCR involves fluid buildup under the retina causing vision distortion and blurriness. Average recovery time was 2.3 months, and recurrence was observed in patients who resumed follistatin use. The authors concluded that follistatin-344 injection should be considered a risk factor for CSCR (Dag et al. 2020, PubMed 32671599). Anyone experiencing visual changes should discontinue immediately and consult an ophthalmologist.

Activin suppression beyond muscle: Activin regulates wound healing, immune function, and erythropoiesis (red blood cell production). Broadly suppressing activin signaling could have effects beyond muscle. Follistatin's isoform-specific distribution provides some protection, but high-dose exogenous follistatin may override this selectivity.

WADA status: Follistatin is listed on the World Anti-Doping Agency (WADA) Prohibited List under S4.3 (Metabolic Modulators). Athletes subject to anti-doping testing must not use follistatin in any form. Testing methods can detect both the recombinant protein and evidence of gene therapy delivery.

Product quality concerns: A WADA-funded analysis of black market follistatin products found that only 9 out of 17 tested samples actually contained functional follistatin protein (PubMed 31758732). Nearly half of commercial products may contain degraded, counterfeit, or mislabeled material. Sourcing from reputable suppliers with third-party certificates of analysis is critical.

Follistatin 344 should not be used by individuals with active cancer, as myostatin inhibition may theoretically promote tumor growth in certain contexts. Individuals with cardiovascular disease, liver disease, or hormonal conditions should consult a physician before use.

Unlike GHRPs that require cycling due to receptor desensitization (see our hexarelin dosage guide for a detailed example), follistatin cycling is primarily about cost management and safety margin rather than receptor dynamics.

Myostatin does not develop resistance to follistatin binding. The reason for cycling is threefold:

1. 1.Cost: At $200-600 per cycle, continuous use is expensive. Cycling allows the body to consolidate gains during off periods.
2. 2.FSH recovery: Off-cycle periods allow pituitary FSH to normalize, protecting reproductive function.
3. 3.Unknown long-term effects: With no long-term human data, periodic breaks are the conservative approach.

Recommended cycling schedule:

During off-cycle periods, muscle gains from follistatin tend to be well-retained because the underlying mechanism (satellite cell activation, myonuclear addition) creates structural changes in muscle fibers. This contrasts with gains from growth hormone secretagogues, which may partially reverse when the GH stimulus is removed.

Stacking follistatin with growth-promoting peptides during the same period is practiced but increases both cost and the complexity of monitoring. Common stacking partners include IGF-1 LR3 for synergistic muscle growth or CJC-1295 + ipamorelin for GH axis support. See our peptide stack calculator for compatibility checking.

This question appears frequently and the answer is straightforward. For injectable use, FS-344 and FS-315 are functionally equivalent because FS-344 converts to FS-315 in the bloodstream.

The practical reason FS-344 dominates the market: it is easier to produce as a stable recombinant protein and has the larger evidence base from gene therapy research. FS-315 is the bioactive downstream product, but injecting the precursor (FS-344) and letting the body do the conversion is the established approach.

If a vendor offers "follistatin 315" at a significantly lower price, verify purity and source carefully. The less common product carries higher risk of quality issues simply due to smaller production volumes and less standardized manufacturing.

Follistatin research spans gene therapy, animal models, and limited human observational data. No randomized controlled trial has tested injectable FS-344 in humans.

The strongest evidence comes from the primate gene therapy study (Kota 2009), which demonstrated durable muscle increases with a single treatment and no safety concerns over the monitoring period. Translating this to injectable peptide protocols requires assumptions about bioavailability and dosing equivalence that have not been validated in controlled settings.

For comparison, IGF-1 LR3 has a somewhat stronger human evidence base for injection protocols, though it works through a different mechanism (direct anabolic signaling rather than myostatin inhibition).